During National Canine Lymphoma Awareness Month in November, biotech company PharmAust Ltd is putting the call out for more pet dogs to help evaluate a new anti-cancer drug shown to be safe and effective in Phase 1 and advanced Phase 2 clinical trials.
The ongoing Phase 2 trial for the drug monepantel (MPL) is finalising dose optimisation and is a prelude to a multi-institutional canine cancer Phase 3 trial to start early next year.
The trial’s principal investigator Dr Kim Agnew is leading a team of veterinary oncologists in NSW, QLD and WA who are evaluating MPL in dogs that have been newly diagnosed with B-cell lymphoma and have not started any treatment.
“The key to a good prognosis with canine lymphoma is early diagnosis and this particular form of cancer is very rapidly progressive, so it’s important to act quickly,” Dr Agnew said.
MPL shown to be a safe and effective cancer treatment, and is already approved for veterinary use for a different indication and species. PharmAust is aiming to repurpose MPL as a safe and effective cancer treatment.
“During the trials to date, over 25 pet dogs have been treated with MPL for lymphoma and the results are very promising,” Dr Agnew said.
“So far, we have shown that the new MPL tablet is very palatable and easy for pet owners to administer at home. Furthermore, at the recently identified optimal drug blood levels, side effects seem to be very minimal and all pet dogs that have maintained these levels over the course of treatment, have been assessed as at least stable disease by the administering veterinarians.
“Some pet dogs have continued after the trial on a combination of this optimum level of MPL and prednisolone, and all have exceeded the life expectancy of dogs that might be administered only prednisolone at diagnosis.”
PharmAust was pleased to successfully meet its predetermined interim goals demonstrating both significant objective clinical benefit and significant overall response rate. It is now inviting more dogs with treatment naïve lymphoma to help complete the final optimisation of the Phase 2 trial in a bridging program before moving into the Phase 3 trial.
The canine entry criteria for MPL clinical trials can be found here.
The MPL program currently involves three consultations at the clinical trial sites (admission, at two weeks and at four weeks). These clinical trial sites are listed here.
For more information or to enrol, please contact Dr Richard Mollard on firstname.lastname@example.org